To Test or Not To Test – Avoiding Costly Planning Mistakes with Effective Dx Financial Pre-Launch Planning - Diaceutics
+

To Test or Not To Test – Avoiding Costly Planning Mistakes with Effective Dx Financial Pre-Launch Planning

May 26th, 2016

Peter Keeling
Mark Reis
Sanna Jousi


Are you at the pre-launch or commercial implementation stage of planning for a therapy and diagnostic? This webinar provides insights on how to optimize your therapy launch to maximize the therapy’s revenue opportunity.

Listen to the webinar to learn:

  • About effective financial planning for integrating diagnostics into your targeted therapy commercial strategy; and
  • That through optimization of the diagnostic, pharma can predict the revenue and patient share losses and gains that can be made in key markets and maximize the return on investment for the therapy asset.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications